Mizuho raised the firm’s price target on Sarepta (SRPT) to $31 from $26 and keeps an Outperform rating on the shares. The firm updated the company’s model to incorporate its 2026 guidance for product sales and operating expenses.
Claim 55% Off TipRanks
Trade SRPT with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target raised to $9 from $8 at Citi
- Controversial Prasad leaving FDA, NYT reports
- Sarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty
- Sarepta Therapeutics Eyes 2026 Reset After Rocky Year
- Sarepta price target lowered to $29 from $34 at Wedbush